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ABSTRACT 
 
 
 Gadd45-α is a tumor suppressor protein identified by microarray analysis with a reduced 
expression in hepatocellular carcinoma (HCC) cell lines with high migration ability.  The role of 
Gadd45-α in HCC migration was tested by stable shRNA knockdowns in a non-metastasizing 
murine cell line (BL185).  The migration levels of the Gadd45-α knockdowns were significantly 
increased relative to the parental non-metastasizing line, indicating that decreased Gadd45-α 
expression is sufficient to promote increased cell migration. 
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BACKGROUND 
 
Liver Cancer 
 Hepatocellular carcinoma (HCC) is a leading cause of cancer deaths worldwide, as 7
th
 
leading cause in Males and 9
th
 leading cause in females (Leong and Leong, 2008).  This type of 
carcinoma is particularly concerning due to the fairly low survival rates (only 11% survival at 5 
years post diagnosis) and few treatment options (ACS, 2008). The incidence of HCC in the 
developed world has increased in the past two decades. The occurrence in the United States has 
seen a 70% increase since 1988, with half of all cases in the United States relating to hepatitis C 
disease (Leong and Leong, 2008). Hepatitis C and Hepatitis B (the latter for which a vaccine 
exists) are more likely to affect HCC rates in developing countries where vaccines or prevention 
may not be available. Hepatitis and liver cirrhosis are often implicated as causing, or as a 
comorbidity with, HCC, likely due to the damage in cells resulting in mutations. According to 
Leong, cirrhosis underlies 80-90% of liver cancers. Cirrhosis can be caused by prolonged alcohol 
abuse, hepatitis infection, or other diseases resulting in damage to the liver. Hepatitis B infection 
causes a 200-fold increase in risk for HCC (Leong and Leong, 2008). These comorbidities often 
are central to the low survival rate.  
 In addition to hepatitis and cirrhosis, there are not many other known causes of HCC 
(Leong and Leong, 2008).  An increase in the incidence of HCC in males makes it 4-8 times 
more likely that a male will have HCC than a female. Exposure to chronic high levels of 
aflatoxins produced by A. flavis and A. parasitans can also increase the incidence of HCC 
(Leong and Leong, 2008). Beyond these known risk factors, causation is not well understood.  
The incidence of metastasis to sites outside the liver in HCC has been reported in greater than 
50% of autopsies (Kummar and Shafi, 2003). This is of great concern because the increase in 
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metastasis parallels a decrease in survival.  HCC commonly metastasizes to lungs, lymph nodes, 
adrenal glands, and bones.  
 The primary treatment of liver cancer is surgery to partially resect the liver, removing the 
tumor and leaving healthy liver to continue important body functions or performing a complete 
liver transplant.  In cases where the liver is also otherwise damaged (i.e. by cirrhosis) or 
metastasis is present, resection or transplantation is not possible, greatly reducing survival rates. 
These patients have limited treatment options, including chemotherapy which has a generally 
poor response. 
 
Tumor Cell Migration 
 Metastasis is the colonization of tumor cells at a site other than that of the primary tumor. 
Metastasis causes the majority of cancer-related deaths, and is therefore of great interest in 
research (Cancerquest, 2008). The ability of a tumor cell to migrate to a new part of the body, 
survive in that new location, and subsequently proliferate is very rare in individual tumor cells. 
However, at the tissue level the reason metastases are not unusual in cancer progression is that 
many cells will acquire the ability to move out of the tumor. Even if only a small fraction of 
these can go on to survive and grow new tumors, the vast numbers initially migrating and 
circulating in the blood make metastasis much more likely on the whole. In order for a cell to 
migrate it must be able to shift its cytoskeleton and have alterations in adhesion molecules on the 
cell surface. The cell must be able to crawl along other cells by attaching to new ones while 
simultaneously letting go of old ones. Once a cell can do this, it can move within the affected 
tissue, however in order to leave the tissue it first must be able to secrete enzymes that digest 
basement membranes made primarily of proteins and glycoproteins. The enzymes that digest the 
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basement membrane are called matrix metalloproteases (MMP). If a cell is able to secrete 
MMPs, then it has the opportunity to enter the blood stream or lymph system by squeezing 
between the cells that form the walls of the small vessels. Once in the blood or lymph, the cell 
circulates through the body and will often exit the circulatory system into a new location. If the 
cell can adapt to live and thrive in the new location, it can multiply and grow a metastatic tumor 
(Cancerquest, 2008).  Metastatic tumors decrease survival because it is often difficult or 
impossible to remove all metastases by surgery or chemotherapy, leaving cancer cells to 
repopulate as new tumors. Metastatic tumors can also inhibit body function depending on 
location. For example, a large metastatic tumor in the lung would interfere with respiratory 
system functions in addition to any effects the original tumor has on function. 
 Many known biological pathways play a role in tumor cell migration and invasion 
phenotypes, which are important properties of metastatic cells. Of particular interest are the 
pathways that play a role in the Epithelial-Mesenchymal Transition (EMT). EMT is a transition 
in which epithelial cells lose the gene profile and phenotype of epithelial cells and gain that of 
mesenchymal cells. EMT is a normal process in wound healing and development, however in the 
context of tumor progression EMT is indicative of metastatic potential (Weinberg, 2007). Some 
of the signaling pathways involved in EMT are shown in Figure 1. The main pathways include 
the FGF/Ras pathway and Wnt/GSK-3β pathway for which the initiator molecules are potentially 
secreted by fibroblast cells located in the stroma, the EGF/Ras pathway for which the initiator 
molecule is potentially secreted by macrophages located in the stroma, the TGF-β pathway for 
which TGF-β is possibly secreted by myofibroblasts located in the stroma, and the TNF-α/NF-
κB pathway for which the molecules are probably secreted by inflammatory cells in the stroma 
and all of which act on the epithelia tumor cells (Weinberg, 2007).  
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Figure 1: Signaling Pathways that Trigger EMT.  The main pathways include 
the FGF/Ras pathway and Wnts/GSK-3β pathway which are potentially induced 
by fibroblast cells in the stroma, the EGF/Ras pathway which is potentially 
induced by macrophages in the stroma, the TGF-β pathway which is possibly 
induced by myofibroblasts in the stroma, and the TNF-α/NF-κB pathway which 
is possibly induced by inflammatory cells in the stroma (Weinberg, 2007). 
 
Protein Gadd45-α 
 A protein termed Growth Arrest and DNA-Damage 45-Alpha (Gadd45-α) is a nuclear 
protein important to genomic stability, DNA repair, and suppression of cell growth (Gramantieri 
et al., 2005). The gene is located on chromosome 1 in humans, and on chromosome 6 in mice 
(NCBI, 2010).  The gene includes 4 exons, and encodes the Gadd45-α protein which has 165 
amino acid residues and is 18 kDa (GeneCards, 2009). The 3D structure of the Gadd45-α protein 
is shown in Figure 2 (Jmol, 2009), and includes five alpha helices and a central beta sheet.   
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Figure 2: The Proposed 3D Structure of Protein Gadd45-α. Red coils 
represent alpha helix structures and yellow arrows denote the beta sheet area. 
(Jmol, 2009) 
  
 Gadd45-α expression is mediated by p53-independent and –dependent pathways 
(GeneCards, 2009). Gadd45-α is often activated in response to DNA-damage and plays a role in 
cell cycle regulation.  If DNA damage has occurred, Gadd45-α can inhibit a cell’s entry into S-
phase preventing the cell from completing mitosis (Gramantieri et al., 2005). Gadd45-α also 
plays a role in activating the G2 check point (Gramantieri et al., 2005), which indicates further 
roles in controlling cell cycle progression. These known cell cycle regulation properties of 
Gadd45-α implicate the protein in the induction of cell cycle arrest and the reduction of cell 
growth (Gramantieri et al., 2005).  These functions point to Gadd45-α as a known important 
player in tumor suppression (Hildesheim et al., 2004). 
 
Potential Role of Gadd45 in HCC 
 The role of Gadd45-α in HCC has been investigated in regard to the relationship between 
cirrhosis and HCC, and DNA repair and cell proliferation (Gramantieri et al., 2005).  The 
investigation reported that DNA repair using Gadd45-α is likely ongoing in HCC, and that 
76.9% of HCCs show a down-regulation of Gadd45-α mRNA compared with cirrhotic tissue 
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(Gramantieri et al., 2005). Unfortunately, a correlation between mRNA levels and protein levels 
was not made, due to what the authors state is an inability of Gadd45-α protein to be detected 
when it is actively participating in DNA repair (Gramantieri et al., 2005). According to the 
GeneCards entry (GeneCards, 2009) on Gadd45-α, its levels in normal liver in comparison to 
liver cancer are similar, illuminating the mostly unknown role of Gadd45-α in HCC (GeneCards, 
2009). However, there may be in fact an up-regulation of Gadd45-α in liver cirrhosis when 
compared to normal liver, leading to what Gramantieri et al. report as a down-regulation of 
Gadd45-α in HCC when compared to cirrhosis, while GeneCards reports no change between 
normal liver and HCC, but the distinction is not yet clear.  
 
Potential Role of Gadd45 in Cell Migration 
 In addition to its role as a tumor suppressor blocking the cell cycle and cell growth, 
Gadd45-α has also been implicated in inhibiting cell migration and the invasion of keratinocytes 
(Hildesheim et al.,2004). It was shown that murine Gadd45-α-null keratinocytes migrate 1.7-fold 
faster in vitro than wild type keratinocytes, indicating Gadd45-α may play an important role in a 
cell migration pathway. This is further supported by the inhibition in migration when Gadd45-α 
is over-expressed in the Gadd45-α-null keratinocytes.  Additionally, Hildesheim et al. 
demonstrate that Gadd45-α-null keratinocytes express higher levels and activities of some types 
of MMPs (2004). Thus, Gadd45-α may play a role in the suppression of MMPs (to inhibit EMT 
as previously mentioned).  This paper also implicates Gadd45-α in a cell migration pathway 
which regulates β-catenin (as seen in the brown box in Figure 1) and therefore EMT. The 
proposed cell migration pathway by Hildesheim et al. is shown in Figure 3, and proposes that 
Gadd45-α activates GSK3β of the wnt pathway to block β-catenin, preventing β-catenin from 
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promoting MMP expression (2004).  Although Gadd45 may play a role in inhibiting the invasion 
of keratinocytes, its potential role in inhibiting HCC migration is currently unknown. 
 
 
Figure 3: Proposed Role of Gadd45-α in a Cell Migration Pathway.  
Gadd45-α antagonizes the wnt pathway to block GSK3β, increasing the 
blockage of β-catenin, to decrease the activity of metastasis promoting 
MMPs (Hildesheim et al., 2004). 
 
Lewis Lab HCC Research 
 The study of HCC tumor cell migration is important to enhance HCC survival rates. 
Previously, members of Dr. Brian Lewis’ lab at the University of Massachusetts Medical School 
(Worcester) described a cell line derived from HCC, induced by PyMT in the liver of a p53-null 
mouse. This BL185 cell line is derived from a non-metastatic tumor, and was selected for two 
subpopulations of cells that had significantly higher (10-fold) in vitro migration and invasion 
activities. The higher migrating and invading subpopulations are called BL185-M1, and BL185-
 12 
I1.  A gene expression microarray assay was performed on these cell lines which showed 
expression differences (greater than a 2-fold change) in 313 genes between the original BL185 
line and either BL185-M1 or BL185-I1 (Lewis, unpublished data).   One gene identified by the 
microarray analysis as having a 20.8-fold down-regulation (p=0.006) in the BL185-M1 
subpopulation, and a 12.4-fold down regulation (p=0.0135) in the BL185-I1 subpopulation is 
Gadd45-α.  Due to its previously described roles in keratinocyte cell migration in other 
carcinomas (discussed previously), this gene is of interest to the Lewis lab as a potential 
regulator of HCC cell migration and metastasis. 
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PROJECT PURPOSE 
 
 Gadd45-α has been shown to inhibit keratinocyte cell migration, but its potential role in 
inhibiting HCC cell migration has not been demonstrated.  The expression of Gadd45-α is down-
regulated in about 76.9% of HCCs compared with cirrhotic tissue (Gramantieri et al., 2005), but 
that study did not address cell migration.  The hypothesis of this project is that Gadd45-α is 
important to cell migration in HCC. This will be investigated by creating stable shRNA 
knockdown of Gadd45-α in the non-metastatic BL185 cell line to discover whether a lack of 
Gadd45-α is sufficient to induce cell migration.  
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METHODS 
Migration Assay 
 5 x 10
4
 cells/ml in 500 μl DMEM was added to BD BioCoat Control inserts. These 
inserts were in individual wells and are part of a 24-well plate. 750 μl of DMEM supplemented 
with 10% Fetal Bovine Serum (FBS) and 1% penicillin/streptomycin (p/s) was added to each 
well. After 20-24 hour incubation, the media was removed from the inserts, and wells and the 
cells were fixed with methanol, stained with Gimesa reagent, and the inner side of the inserts was 
swabbed to remove non-migrating cells. The membranes of the inserts were removed and slides 
were created for counting under 100X magnification. The samples were performed in duplicate 
or triplicate for each assay repetition. 
Cell Culture 
 All cells were incubated at 37°C and 5% CO2 in DMEM supplemented with 10% FBS 
and 1% p/s. Additionally, the BL185-clone (1,2,3,4,5,GFP) cells had 8 μg/ml puromycin added 
to the media. 
Isolation of Cell Lystates for Western Blot 
 After pelleting the cells, the pellet was re-suspended in 100-300 μl of RIPA buffer, and 
incubated on ice for 30 minutes. After the incubation, all samples were centrifuged to pellet the 
lipids leaving the protein in the supernatant, which was saved.  Total protein concentration was 
determined using the Bradford assay.  
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Western Blot 
 Cell lysate was added to 4x sample buffer and incubated at 100°C for 10 minutes. These 
samples were then run on a 12% acrylamide gel. The protein was then transferred to a PVDF 
transfer membrane from GE Healthcare using wet transfer for 1 hour at 100 Volts and 4°C. The 
membrane was blocked using 5% dry non-fat milk in 20ml TBS-T at 4°C overnight with 
shaking. Primary antibody (Table 1) was then added at a concentration of 1:500 for Gadd45-α 
and 1:1000 for Actin in 5% dry non-fat milk in 10 ml of TBS-T. This was incubated for 1 hour at 
room temperature with shaking. The membrane was then washed 3 times for 10 minutes each 
with TBS-T. Secondary antibody (Anti-rabbit IgG antibody from Cell Signaling) was then added 
to the membrane at a concentration of 1:5000 in 10 ml of 5% dry non-fat milk in TBS-T. This 
was incubated for 1 hour at room temperature with shaking. The membrane was then washed 3 
times for 20 minutes each with TBS-T at room temperature with shaking. SuperSignal West 
Femto Maximum Sensitivity Substrate from Thermo Scientific was then added to the membrane 
for 30 seconds. The membrane was then developed in a dark room using Kodak Scientific 
Imaging Film. The developing time was about 1 minute. 
 
Protein Probed for Primary Antibody 
Gadd45-α GADD 45α (H-165) Rabbit polyclonal IgG from Santa Cruz Biotechnology 
Actin Actin (C-11)-R Rabbit polyclonal IgG from Santa Cruz Biotechnology 
Table 1: Primary Antibodies used for Western Blot 
Proliferation Assay 
 The proliferation assay was performed by adding 1000cells/well in 100 μl DMEM with 
10% FBS and 1% p/s to the wells of a collagen-coated 96-well plate. For each sample at each 
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time point triplicate wells were assayed. For each time point the media was removed and 50 μl 
DMEM supplemented with 10% FBS and 1% p/s was added along with 10 μl MTS reagent, then 
samples were incubated for 30 minutes at 37°C and 5% CO2. The absorbance of the wells of 
interest was then obtained using a plate reading spectrophotometer set to 490 nm. 
Soft Agar Assay 
 A hard agar base was established by adding 7 ml of 1.4% agar with 2x DMEM to a 10-
cm plate. Upon hardening a 3 ml soft agar layer was added containing 0.8% agar, 2x DMEM, 
and 1X10
5
 cells to each plate. After this layer hardened 8 ml 1x DMEM was added to the plate 
and incubated for 3 weeks at 37°C and 5% CO2.  After incubation, colonies in 10 fields per plate 
were counted at 10X magnification using size exclusion. For each sample two plates were 
prepared and counted. 
shRNA Infection 
 Five shRNA constructs obtained from Open Biosystems were used in addition to a GFP 
plasmid. The shRNA constructs correspond to the identification numbers as outlined in Table 2. 
Construct (Clone) number Identification number 
1 TRCN0000054688 
2 TRCN0000054689 
3 TRCN0000054690 
4 TRCN0000054691 
5 TRCN0000054691 
Table 2: Open Biosystems Identification Numbers for shRNA constructs 
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 Once the plasmids containing the shRNAs were isolated from bacteria they were each 
added to a mix of pMPG, pCMV, effectene transfection reagent and enhancer. These mixes were 
then added to 293T cells, and incubated at 37°C and 5% CO2 overnight. The media was then 
changed, and the cells incubated for 48-72 hours, after which the retroviral supernatant was 
harvested and sterilized. The sterilized supernatant with polybrene was added to the target 
(BL185) cells and incubated at 37°C and 5% CO2 for 5 hours. After this incubation period, the 
supernatant was removed and normal media was added and incubated as usual. Puromycin was 
added to the media after the first day incubation. The cells were thereafter referred to as BL185-
Clone 1, BL185-Clone 2, BL185-Clone 3, BL185-Clone 4, BL185-Clone 5, BL185-Clone GFP. 
Quantitative Real Time-Polymerase Chain Reaction 
 Total cellular RNA was isolated from cultured cells using triozol, chloroform, and finally 
isopropanol. The RNA was purified using RNeasy Qiagen kit and then the TURBO DNA-free 
protocol. The RNA was then converted into first strand cDNA using superscript III First-Strand 
Synthesis System for RT-PCR. This cDNA was then used for Quantitative Real Time-PCR using 
TaqMan Universal PCR Master Mix from Applied Biosystems, Mouse ACTB primer from 
Applied Biosystems (Actin) or the qRT-PCR kit for Gadd45-α from Applied Biosytems 
(Gadd45-α) and 10 ng/μl of cDNA. The prepared samples (in triplicate) were then analyzed on a 
7300 Real Time PCR System machine with matching software from Applied Biosystems. The 
PCR cycle was as indicated in Table 3. Data collection occurred at stage 3, step 2. 
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Stage/step Stage 1 Stage 2 Stage 3/step 1 Stage 3/Step 2 
Number of Repeats 1 1 40 (for stage 3) (40 for all of stage 3) 
Temperature 50°C 95°C 95°C 60°C 
Length 2 minutes 10 minutes 15 Seconds 1 minute 
Table 3: qRT-PCR Conditions 
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RESULTS 
 
 The purpose of this project was to determine if Gadd45-α levels in a hepatocellular 
carcinoma (HCC) cell line effect the migratory tendency of those cells. In order to explore this 
question, a HCC cell line lacking Gadd45-α needed to be created. This was done through stable 
shRNA knockdown using the shRNAs indicated in the methodology. The knockdown was 
verified using qRT-PCR in comparison to the GFP-infected BL185-Clone GFP cell line. Figure 
4 is a representative graph of the qRT-PCR for BL185-Clone 2 and BL185-Clone 3 compared to 
BL185-Clone GFP, showing reduced levels of the Gadd45-α mRNA in both shRNA-infected cell 
lines. The qRT-PCR was also run for BL185-M1 and BL185-I1 cell lines, providing 
confirmation of microarray data in Table 4. 
 
Figure 4: qRT-PCR of Gadd45-α Levels in shRNA Cells Compared with BL185-
Clone GFP.  Representative data of qRT-PCR of Gadd45-α mRNA levels for BL185-
Clone 2 and BL185-Clone 3 shown as a fold change relative to BL185-GFP.   
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Cells compared to 
BL185  
Micro Array (fold 
change)  
P-Value for 
MicroArray  
qRT-PCR (fold 
change)  
BL185-M1  -20.8119  0.006  -1.587  
BL185-I1  -12.4344  0.0135  -3.603  
Table 4: Microarray and qRT-PCR Confirmation of microarray data for Gadd45-α mRNA levels for the high 
migrating cell lines BL185-M1 and BL185-I1.  
 
 In order to confirm knockdown of Gadd45-α protein, a western blot was performed. As 
seen in                      Figure 5, the level of Gadd45-α is greatly decreased in the shRNA 
knockdowns BL185-Clone 2 and –Clone 3 in comparison to the BL185-Clone GFP. The actin 
levels for these samples are fairly similar as well, ensuing equal amounts of sample were loaded 
in each lane. The western blot confirmation of knockdown is important because some shRNAs 
do not degrade mRNA, but rather bind to it preventing translation of the protein and effectively 
inhibiting the function. In this case, the qRT-PCR and western blot data together confirm that the 
targeted shRNAs reduce Gadd45-α levels. 
 
                     Figure 5: Gadd45-α Western Blot. 
 
Upon confirmation of knockdown in the BL185-Clone 2 and BL185-Clone 3 cell lines, 
the characteristics of these cell lines in comparison to the parental BL185, BL185-M1 (high 
migrating), BL185-I1 (high migrating), and BL185-Clone GFP (control) cells was of interest. A 
soft agar assay was performed to determine the degree of transformation of the cells. Cancer 
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cells are typically considered to have a relatively high transformation rate, but additional 
transformation is possible. Figure 6 shows that the level of transformation of the cell lines is 
similar. However, the BL185-I1 cell line (3
rd
 histobar) has significantly (p=0.01) less colonies 
than the other cell lines. This assay was only preformed once, so an explanation of this anomaly 
is not available. Overall these data suggest that reduction of Gadd45-α levels does not have a 
significant effect on transformation in the established HCC cell lines. 
 
 
Figure 6: Soft Agar Assay.  The number of transformed colonies (Y-axis) is fairly 
consistent between all cell lines for one trial of this assay 
 
 In order to compare the rate of growth for each cell line, a cell proliferation assay was 
performed ( 
Figure 7). Proliferation is important for better understanding the effect that reduction of Gadd45-
α has on the cells ability to divide. This is of particular interest because of the role Gadd45-α is 
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known to play in the activation of cell cycle checkpoints and therefore prevention of 
proliferation. The rate of cell division was found to be similar at 24 hours for each cell line, but 
diverges after 48-120 hours. The proliferation assay revealed similar growth rates for BL185-
Clone 2, BL185-Clone 3, and BL185-GFP after 24 hours (P=0.4). This is of relevance for the 
migration assay, which was incubated for 24 hours. The cell division differences between cell 
lines increases after 24 hours until becoming similar at about 5 days (upon confluence). The most 
striking difference is an increased proliferation observed for shRNA BL185-Clone 3, potentially 
relating to the additional role of Gadd45-α in preventing proliferation. This assay was performed 
twice for the 24, 48, and 72 hour time points. 
 
 
 
Figure 7: Proliferation Assay.  The cell lines at 24 hours have the same growth rate, but 
diverge after 24 hours before converging again after 120 hours when confluence occurs.  
The assay was performed twice at the 24, 48, and 72 hr time points.  Error bars denote 
one standard deviation. 
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 Finally, with the characterization of the knockdown cell lines complete, migration assays 
were performed to assess the effect of Gadd45-α knockdown on migration. Migration is an 
important characteristic of metastasis of tumor cells, and is therefore often used as an indicator 
for metastasis in vitro.  
Figure 8 shows a graph of a single assay which is representative of the overall trend.  This figure 
shows that both shRNA clones (BL185-Clone 2 and BL185-Clone 3) have increased migration 
over control BL185-GFP. When all repetitions of this assay were compiled, the results show a p-
value of 0.05 for BL185-Clone 2, and 0.025 for BL185-Clone 3. This indicates that the increase 
in migration of the Gadd45-α knockdowns over the GFP infection is significant. 
 
 
 
Figure 8: Representative Graph of the Cell Migration Assay.  Representative data 
showing the trend observed in which Gadd45-α knockdown clones BL185-Clone 2 and 
BL185-Clone 3 have a significant increase in cell migration compared to control BL185-
Clone GFP.  Error bars denote one standard deviation. 
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DISCUSSION 
 
 
 This project investigated whether a reduction of Gadd45-α levels is sufficient to cause an 
increase in cell migration in HCC cells.  Gadd45-α was chosen as target for knockdown after an 
analysis of the previously mentioned microarray data indicated a significant down-expression of 
Gadd45-α in migrating HCC cells. Gadd45-α was also of interest because of its known role in 
regulating cell cycle checkpoints and DNA damage. The project results revealed that decreasing 
Gadd45-α is sufficient to increase cell migration in HCC murine cell lines. The cell lines with 
Gadd45-α shRNA stable knockdown showed migration levels similar to the high migrating cell 
lines BL185-M1 and BL185-I1, and showed significantly more migration than control BL185-
Clone GFP. The knockdown cell lines had the same level of proliferation at 24 hours as the 
BL185-Clone GFP cell line, which shows that increased migration is not an artifact caused by an 
increase in cell division over the 24 hour incubation period of the migration assay.  This helps to 
confirm the significance of the higher migration in the knockdown cell lines, which had p values 
of 0.05 (BL185-Clone 2) and 0.025 (BL185-Clone 3) when compared with the control clone 
expressing GFP.  These data provide similar results to the paper by Hildesheim et al. (2004) 
which suggested the potential cell migration pathway shown in the Background in Figure 3.  In 
this pathway, Gadd45-α antagonizes wnts preventing the blockage of GSK3β, which in turn 
blocks β-catenin from activating MMPs and other migration-promoting genes. The data from this 
project suggest that decreasing Gadd45-α is sufficient to increase migration in HCC cells. The 
potentially important role in migration suggested by the data poses the possibility that Gadd45-α 
also plays an important role in metastasis of HCC. This is especially important because resection 
or transplantation of the liver to cure HCC is prevented when metastases are present. Increasing 
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the understanding of the mechanisms underlying metastasis in HCC is essential for the future 
prevention of metastasis.  
 The data in this project also reveal the important role that Gadd45-α plays in cell 
proliferation. After 48 hours, one of the knockdown cell lines (BL185-Clone 3) had increased 
proliferation in comparison to the GFP control. This shows that Gadd45-α is an important 
negative regulator of the cell cycle. Because this increase in proliferation does not occur until 
after 24 hours (the length of a migration assay) it seems unlikely that the regulation of migration 
by Gadd45-α is due to its known role in cell cycle regulation. More likely Gadd45-α is 
participating in another pathway such as the one suggested in Figure 3. 
An interesting future investigation may be to over-express Gadd45-α in the migrating cell 
lines (BL185-M1, BL185-I1) to discover if an increased cellular level of Gadd45-α is sufficient 
to prevent cell migration. This approach has been started with attempts to clone the Gadd45-α 
gene and insert it into an appropriate plasmid vector (pBABE-puro) for future infection. 
Unfortunately this process has been difficult and has yet to be completed.  
An additional assay which might provide interesting information would be an invasion 
assay for the knockdown cell lines. The pathway proposed by Hildesheim et al. (2004) (Figure 
3) results in promotion of Matrix Metalloproteinases (MMPs) which are known to degrade 
extracellular matrix proteins. Degradation of extracellular matrix proteins is a recognized 
property important in invasion ability, so the invasion assay may provide additional insight 
regarding the potential mechanism through which a reduction of HCC may facilitate metastasis 
of HCC cells. Additional assays may be performed to determine the levels of other proteins in 
the proposed pathways in the knockdown or to create over-expression cell lines to provide 
insight into the validity of the proposed pathway. 
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